Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study - 27/01/22
Abstract |
Background |
Cutaneous squamous cell carcinoma (cSCC) represents the most serious form of keratinocyte cancers because of its metastatic potential. Studies on nationwide incidence and disease-specific survival rates of metastatic cSCC (mcSCC) are lacking.
Objective |
To investigate the cumulative incidence and disease-specific survival of patients with mcSCC in the Dutch population and assess patient-based risk factors.
Methods |
We conducted a nationwide cancer registry study including all patients with the first cSCC in 2007 or 2008, using data from the Netherlands Cancer Registry, the nationwide network and registry of histopathology and cytopathology, and Statistics Netherlands. Cumulative incidence and Kaplan-Meier curves were calculated, and time-dependent Cox proportional hazards regression analyses were used.
Results |
Of the 11,137 patients, metastases developed in 1.9% (n = 217). The median time to metastasis was 1.5 years (interquartile range 0.6-3.8 years). The risk factors were age (adjusted hazard ratio [aHR] 1.03, 95% CI 1.02-1.05), male sex (aHR 1.7, 95% CI 1.3-2.3), and immunosuppression (aHR [organ transplant recipient] 5.0, 95% CI 2.5-10.0; aHR [hematologic malignancy] 2.7, 95% CI 1.6-4.6). The 5-year disease-specific survival for patients with mcSCC was 79.1%.
Limitations |
Only histopathologically confirmed mcSCCs were included.
Conclusion |
About 2% of cSCCs metastasize, with higher risk for men, increasing age, and immunocompromised patients. Disease-specific survival for patients with mcSCC is high.
Le texte complet de cet article est disponible en PDF.Key words : cancer registry, cutaneous squamous cell carcinoma, epidemiology, hematologic malignancy, incidence, keratinocyte carcinoma, metastasis, organ transplantation, survival
Abbreviations used : aHR, cSCC, mcSCC, IQR, NCR, NMSC, OTR
Plan
| Funding sources: This work was supported by Sanofi Genzyme (grant number SGZ-2018-12154). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. |
|
| IRB approval status: This study was approved by the scientific committees of the Netherlands Cancer Registry, PALGA, Dutch Transplant Foundation, Erasmus Medical Center (MEC-2020-0054), and Dutch Clinical Research Foundation (W20.048/NWMO20.02.007) and was granted a waiver of informed consent following the code of conduct of the Foundation Federation of Dutch Medical Scientific Societies. |
|
| Reprints not available from the authors. |
Vol 86 - N° 2
P. 331-338 - février 2022 Retour au numéro
Article précédent
- The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris
- Kristina Navrazhina, Sandra Garcet, John W. Frew, Xiuzhong Zheng, Israel Coats, Emma Guttman-Yassky, James G. Krueger
- A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis
- John Q. Lin, Shirley Q. Li, Shufeng Li, Eileen F. Kiamanesh, Sumaira Z. Aasi, Bernice Y. Kwong, Anne Lynn Su Chang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?